VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT05156125 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

213

Enrollment

INDUSTRY

Sponsor class

Stopped The Induction and Long-Term Extension Periods were completed and analyzed as planned. The Sponsor decided to terminate clinical conduct in the Open-Label Extension Period. The decision to terminate the study was not due to safety concerns.

Conditions

Colitis, Ulcerative

Interventions

DRUG: VTX002
DRUG: VTX002
DRUG: Placebo

Sponsor

Oppilan Pharma Ltd